Evidence map›Paper›PMID 26865594›Full record

ArticleClinical and vaccine immunology : CVI2016

Humoral and Cell-Mediated Immune Responses to Alternate Booster Schedules of Anthrax Vaccine Adsorbed in Humans.

Conrad P Quinn, Carol L Sabourin, Jarad M Schiffer, Nancy A Niemuth, Vera A Semenova, Han Li, Thomas L Rudge, April M Brys, Robert S Mittler, Chris C Ibegbu and 12 more

Registry-linked trialOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and vaccine immunology : CVI, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00119067 (Anthrax Vaccine Adsorbed), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00119067 phase4completednot on this map

Anthrax Vaccine Adsorbed: Human Reactogenicity and Immunogenicity Trial to Address Change in Route of Administration and Dose Reduction

TypeinterventionalSponsorCenters for Disease Control and PreventionRan2002 to 2010Enrolled1,564ConditionsHealthyArmsAnthrax Vaccine Adsorbed, Saline injection
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 7 institutions in 1 country.

Conrad P QuinnCenters for Disease Control and Prevention, Atlanta, Georgia, USA cquinn@cdc.gov.
Carol L SabourinBattelle, Columbus, Ohio, USA.
Jarad M SchifferCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Nancy A NiemuthBattelle, Columbus, Ohio, USA.
Vera A SemenovaCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Han LiCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Thomas L RudgeBattelle, Columbus, Ohio, USA.
April M BrysBattelle, Columbus, Ohio, USA.
Robert S MittlerEmory Vaccine Center, Emory University, Atlanta, Georgia, USA Yerkes National Primate Center, Emory University, Atlanta, Georgia, USA.
Chris C IbegbuEmory Vaccine Center, Emory University, Atlanta, Georgia, USA Yerkes National Primate Center, Emory University, Atlanta, Georgia, USA.
Jens WrammertEmory Vaccine Center, Emory University, Atlanta, Georgia, USA.
Rafi AhmedEmory Vaccine Center, Emory University, Atlanta, Georgia, USA.
Scott D ParkerUniversity of Alabama at Birmingham, Birmingham, Alabama, USA.
Janiine BabcockWalter Reed Army Institute for Research, Silver Spring, Maryland, USA.
Wendy KeitelBaylor College of Medicine, Houston, Texas, USA.
Gregory A PolandMayo Clinic, Rochester, Minnesota, USA.
Harry L KeyserlingEmory University School of Medicine, Atlanta, Georgia, USA.
Hana El SahlyBaylor College of Medicine, Houston, Texas, USA.
Robert M JacobsonMayo Clinic, Rochester, Minnesota, USA.
Nina MaranoCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Brian D PlikaytisCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Jennifer G WrightCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Centers for Disease Control and Prevention · USEmory University · USBattelle · USBaylor College of Medicine · USMayo Clinic · USUniversity of Alabama at Birmingham · USWalter Reed Army Institute of Research · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protective antigen (PA)-specific antibody and cell-mediated immune (CMI) responses to annual and alternate booster schedules of anthrax vaccine adsorbed (AVA; BioThrax) were characterized in humans over 43 months. Study participants received 1 of 6 vaccination schedules: a 3-dose intramuscular (IM) priming series (0, 1, and 6 months) with a single booster at 42 months (4-IM); 3-dose IM priming with boosters at 18 and 42 months (5-IM); 3-dose IM priming with boosters at 12, 18, 30, and 42 months (7-IM); the 1970 licensed priming series of 6 doses (0, 0.5, 1, 6, 12, and 18 months) and two annual boosters (30 and 42 months) administered either subcutaneously (SQ) (8-SQ) or IM (8-IM); or saline placebo control at all eight time points. Antibody response profiles included serum anti-PA IgG levels, subclass distributions, avidity, and lethal toxin neutralization activity (TNA). CMI profiles included frequencies of gamma interferon (IFN-γ)- and interleukin 4 (IL-4)-secreting cells and memory B cells (MBCs), lymphocyte stimulation indices (SI), and induction of IFN-γ, IL-2, IL-4, IL-6, IL-1β, and tumor necrosis factor alpha (TNF-α) mRNA. All active schedules elicited high-avidity PA-specific IgG, TNA, MBCs, and T cell responses with a mixed Th1-Th2 profile and Th2 dominance. Anti-PA IgG and TNA were highly correlated (e.g., month 7,r(2)= 0.86,P< 0.0001, log10 transformed) and declined in the absence of boosters. Boosters administered IM generated the highest antibody responses. Increasing time intervals between boosters generated antibody responses that were faster than and superior to those obtained with the final month 42 vaccination. CMI responses to the 3-dose IM priming remained elevated up to 43 months. (This study has been registered at ClinicalTrials.gov under registration no. NCT00119067.).

Indexed as

Immunization ScheduleAnthrax VaccinesAntibodies, BacterialAntigens, BacterialBacterial ToxinsClinical Trials as TopicCohort StudiesCytokinesHumansImmunization, SecondaryImmunoglobulin GInjections, IntramuscularInjections, SubcutaneousLeukocytes, MononuclearNeutralization TestsPlacebosanthrax toxinAnthrax VaccinesAntibodies, BacterialAntigens, BacterialBacterial ToxinsCytokinesImmunoglobulin GPlacebos

Identifiers

PMID26865594
PMCPMC4820509
OpenAlexW2253207932

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.